Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of GSK2402968 in ambulant Duchenne muscular dystrophy patients amenable to exon 51 skipping
2010-020069-26Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2010
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing GSK2402968 with Placebo (2 arms). Primary endpoint: Mean change from baseline in 6-minute walk distance. Started Jun 2010; status: completed.
02
Drugs
drisapersen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2010-020069-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020069-26.